[1]
|
de Camargo B, de Oliveira Santos M, Rebelo MS, et al. Cancer incidence among children and adolescents in Brazil: first report of 14 population-based cancer registries. Int J Cancer, 2010, 126(3): 715-720. |
[2]
|
Li J, Thompson TD, Miller JW, et al. Cancer incidence among children and adolescents in the United States, 2001-2003. Pediatrics, 2008, 121(6): e1470-1477. |
[3]
|
鲍萍萍, 郑莹, 王春芳, 等. 2002~2004年上海市儿童恶性肿瘤发病特征.中国肿瘤, 2009, 18(2): 119-122.
|
[4]
|
Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin, 2010, 60(5): 277-300. |
[5]
|
Higashi T, Kudo T, Kinuya S. Radioactive iodine(131I) therapy for differentiated thyroid cancer in Japan: current issues with historical review and future perspective. Ann Nucl Med, 2012, 26(2): 99-112. |
[6]
|
Chawla SC, Federman N, Zhang D, et al. Estimated cumulative radiation dose from PET/CT in children with malignancies: a 5-year retrospective review. Pediatr Radiol, 2010, 40(5): 681-686. |
[7]
|
Alessio AM, Kinahan PE, Manchanda V, et al. Weight-based, low-dose pediatric whole-body PET/CT protocols. J Nucl Med, 2009, 50(10): 1570-1577. |
[8]
|
Fahey FH. Dosimetry of Pediatric PET/CT. J Nucl Med, 2009, 50(9): 1483-1491. |
[9]
|
Gelfand MJ, Lemen LC. PET/CT and SPECT/CT dosimetry in children: the challenge to the pediatric imager. Semin Nucl Med, 2007, 37(5): 391-398. |
[10]
|
Hahn K, Pfluger T. Is PET/CT necessary in paediatric oncology? Against. Eur J Nucl Med Mol Imaging, 2006, 33(8): 966-968. |
[11]
|
Riad R, Omar W, Kotb M, et al. Role of PET/CT in malignant pediatric lymphoma. Eur J Nucl Med Mol Imaging, 2010, 37(2): 319-329. |
[12]
|
Olson MR, Donaldson SS. Treatment of pediatric hodgkin lymphoma. Curr Treat Options Oncol, 2008, 9(1): 81-94. |
[13]
|
Freed J, Kelly KM. Current approaches to the management of pediatric Hodgkin lymphoma. Paediatr Drugs, 2010, 12(2): 85-98. |
[14]
|
Miller E, Metser U, Avrahami G, et al. Role of 18F-FDG PET/CT in staging and follow-up of lymphoma in pediatric and young adult patients. J Comput Assist Tomogr, 2006, 30(4): 689-694. |
[15]
|
Punwani S, Taylor SA, Bainbridge A, et al. Pediatric and adolescent lymphoma: comparison of whole-body STIR half-FourierRARE MR imaging with an enhanced PET/CT reference for initial staging. Radiology, 2010, 255(1): 182-190. |
[16]
|
Sharma P, Gupta A, Patel C, et al. Pediatric lymphoma: metabolic tumor burden as a quantitative index for treatment response evaluation. Ann Nucl Med, 2012, 26(1): 58-66. |
[17]
|
Mardis N, Wong CY. The accuracy of PET(CT) in evaluating pediatric lymphoma. J Pediatr Hematol Oncol, 2007, 29(9): 667-668. |
[18]
|
Levine JM, Weiner M, Kelly KM. Routine use of PET scans after completion of therapy in pediatric Hodgkin diseaseresults in a high false positive rate. J Pediatr Hematol Oncol, 2006, 28(11): 711-714. |
[19]
|
Riad R, Omar W, Sidhom I, et al. False-positive F-18 FDG uptake in PET/CT studies in pediatric patients withabdominal Burkitt's lymphoma. Nucl Med Commun, 2010, 31(3): 232-238. |
[20]
|
Mody RJ, Bui C, Hutchinson RJ, et al. Comparison of 18F Flurodeoxyglucose PET with Ga-67 scintigraphy andconventional imaging modalities in pediatric lymphoma. Leuk Lymphoma, 2007, 48(4): 699-707. |
[21]
|
Hines-Thomas M, Kaste SC, Hudson MM, et al. Comparison of gallium and PET scans at diagnosis and follow-up of pediatricpatients with Hodgkin lymphoma. Pediatr Blood Cancer, 2008, 51(2): 198-203. |
[22]
|
Morris EB, Gajjar A, Okuma JO, et al. Survival and late mortality in long-term survivors of pediatric CNS tumors. J Clin Oncol, 2007, 25(12): 1532-1538. |
[23]
|
Arora B, Parikh PM. PET-CT scan in pediatric oncology: where, when, how and at what price. Indian J Cancer, 2010, 47(4): 355-359. |
[24]
|
Pirotte BJ, Lubansu A, Massager N, et al. Clinical interest of integrating positron emission tomography imaging in theworkup of 55 children with incidentally diagnosed brain lesions. J Neurosurg Pediatr, 2010, 5(5): 479-485. |
[25]
|
Pirotte BJ, Lubansu A, Massager N, et al. Clinical impact of integrating positron emission tomography during surgery in 85 children with brain tumors. J Neurosurg Pediatr, 2010, 5(5): 486-499. |
[26]
|
Pirotte B, Levivier M, Morelli D, et al. Positron emission tomography for the early postsurgical evaluation of pediatricbrain tumors. Childs Nerv Syst, 2005, 21(4): 294-300. |
[27]
|
Kruer MC, Kaplan AM, Etzl MM Jr, et al. The value of positron emission tomography and proliferation index in predictingprogression in low-grade astrocytomas of childhood. J Neurooncol, 2009, 95(2): 239-245. |
[28]
|
Zukotynski KA, Fahey FH, Kocak M, et al. Evaluation of 18F-FDG PET and MRI associations in pediatric diffuse intrinsicbrain stem glioma: a report from the Pediatric Brain Tumor Consortium. J Nucl Med, 2011, 52(2): 188-195. |
[29]
|
Spence AM, Muzi M, Mankoff DA, et al. 18F-FDG PET of gliomas at delayed intervals: improved distinction between tumorand normal gray matter. J Nucl Med, 2004, 45(10): 1653-1659. |
[30]
|
Utriainen M, Metsahonkala L, Salmi TT, et al. Metabolic characterization of childhood brain tumors: comparison of 18F-fluorodeoxyglucose and 11C-methionine positron emission tomography. Cancer, 2002, 95(6): 1376-1386. |
[31]
|
Phi JH, Paeng JC, Lee HS, et al. Evaluation of focal cortical dysplasia and mixed neuronal and glial tumors inpediatric epilepsy patients using 18F-FDG and 11C-methionine pet. J Nucl Med, 2010, 51(5): 728-734. |
[32]
|
Chen W, Silverman DH, Delaloye S, et al. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET andevaluation of diagnostic accuracy. J Nucl Med, 2006, 47(6): 904-911. |
[33]
|
Walter F, Federman N, Apichairuk W, et al. 18F-fluorodeoxyglucose uptake of bone and soft tissue sarcomas in pediatricpatients. Pediatr Hematol Oncol, 2011, 28(7): 579-587. |
[34]
|
Bestic JM, Peterson JJ, Bancroft LW. Pediatric FDG PET/CT: Physiologic uptake, normal variants, and benign conditions[corrected]. Radiographics, 2009, 29(5): 1487-1500. |
[35]
|
Ricard F, Cimarelli S, Deshayes E, et al. Additional Benefit of F-18 FDG PET/CT in the staging and follow-up of pediatricrhabdomyosarcoma. Clin Nucl Med, 2011, 36(8): 672-677. |
[36]
|
Tateishi U, Yamaguchi U, Seki K, et al. Bone and soft-tissue sarcoma: preoperative staging with fluorine 18fluorodeoxyglucose PET/CT and conventional imaging. Radiology, 2007, 245(3): 839-847. |
[37]
|
Walter F, Czernin J, Hall T, et al. Is there a need for dedicated bone imaging in addition to 18F-FDG PET/CT imaging in pediatric sarcoma patients?. J Pediatr Hematol Oncol, 2012, 34(2): 131-136. |
[38]
|
Bentzen L, Keiding S, Nordsmark M, et al. Tumour oxygenation assessed by 18F-fluoromisonidazole PET and polarographicneedle electrodes in human soft tissue tumours. Radiother Oncol, 2003, 67(3): 339-344. |
[39]
|
Tateishi U, Yamaguchi U, Maeda T, et al. Staging performance of carbon-11 choline positron emission tomography/computed tomography in patients with bone and soft tissue sarcoma: comparison withconventional imaging. Cancer Sci, 2006, 97(10): 1125-1128. |
[40]
|
Lpci E, Piccardo A, Nanni C, et al. 18F-DOPA PET/CT in neuroblastoma: comparison of conventional imaging with CT/MR. Clin Nucl Med, 2012, 37(4): e73-78. |
[41]
|
Levine DS, Metzger DL, Nadel HR, et al. Novel use of F-DOPA PET/CT imaging in a child with paraganglioma/pheochromocytomasyndrome. Pediatr Radiol, 2011, 41(10): 1321-1325. |
[42]
|
Radhakrishnan V, Kumar R, Malhotra A, et al. Role of PET/CT in staging and evaluation of treatment response after 3 cycles of chemotherapy in locally advanced retinoblastoma: a prospective study. J Nucl Med, 2012, 53(2): 191-198. |
[43]
|
Bertagna F, Orlando E, Bosio G, et al. Incremental diagnostic value of F-18 FDG PET/CT over MRI in a pediatric patientwith suspected hepatoblastoma and histologic diagnosis of focal nodularhyperplasia. Clin Nucl Med, 2011, 36(4): 305-308. |
[44]
|
Kumar J, Seith A, Kumar A, et al. Whole-body MR imaging with the use of parallel imaging for detection of skeletal metastases in pediatric patients with small-cell neoplasms: comparison withskeletal scintigraphy and FDG PET/CT. Pediatr Radiol, 2008, 38(9): 953-962. |
[45]
|
Piwkowski P, Kolodziejczyk A, Macioszek A, et al. Potential role of PET-CT in chemotherapy efficacy assessment and recurrencediagnosis in a patient with a Wilms' tumour. Nucl Med Rev Cent East Eur, 2011, 14(1): 33-35. |
[46]
|
Mackie GC, Shulkin BL, Ribeiro RC, et al. Use of 18F-fluorodeoxyglucose positron emission tomography in evaluating locallyrecurrent and metastatic adrenocortical carcinoma. J Clin Endocrinol Metab, 2006, 91(7): 2665-2671. |